The aacC4 gene from Escherichia coli can be expressed in mycobacteria and confers resistance to apramycin. However, the major limitation of the aacC4 gene as a genetic tool is that the gene also confers resistance to kanamycin and gentamicin, two antibiotics commonly used for selection in mycobacterial genetics, thus reducing the utility of the aacC4 gene in the mycobacterial field. To overcome this problem we constructed, by chemical mutagenesis, a mutant allele of the E. coli aacC4 gene that still confers resistance to apramycin but has a reduced ability to confer resistance to kanamycin and gentamicin. We then constructed a variety of E. colimycobacteria shuttle plasmids containing this mutant allele.
Introduction
The development of genetic systems for the analysis of bacteria relies upon selectable marker genes, usually encoding resistance to antibiotics. For a given antibiotic resistance gene to be useful the gene must be sufficiently expressed in the bacterial host and the host should exhibit a low frequency of spontaneous resistance to the particular antibiotic. In the case of pathogenic bacteria, the antibiotic resistance gene of choice should not confer resistance to drugs used to treat infections caused by the organism.
The development of genetic tools for the analysis of mycobacteria has come far in the past decade [1] . Various mycobacteriophage and plasmid systems, reporter genes, transposon mutagenesis and allelic exchange methodologies are in widespread use [2, 3] . However, multiple use of these tools in the same strain is hampered by the availability of enough suitable antibiotic resistance markers. This is due to the inherent resistance of mycobacteria to certain antibiotics used for selection in other bacteria, the instability of some antibiotics during the long incubation times required for slow-growing mycobacteria, and clinical concerns.
The antibiotics most commonly used for selection in mycobacterial genetics are the aminoglycosides kanamycin, hygromycin, and gentamicin. The marker genes used that confer resistance to these antibiotics are the aph, hyg, and aacC1 genes, respectively. The aminoglycoside apramycin is also a useful antibiotic for selection in mycobacteria; the organisms are very susceptible to it, there is a low frequency of spontaneous resistance, the drug is not used to treat mycobacterial infections, and it is stable and relatively inexpensive [4] . The aacC4 gene from Escherichia coli, encoding AAC(3)-IV aminoglycoside acetyltransferase [5] , confers resistance to apramycin and can be expressed in both fast-and slow-growing mycobacteria, including Mycobacterium tuberculosis [4] . The major drawback of the AAC(3)-IV enzyme, however, is that it is capable of acetylating not only apramycin, but kanamycin, gentamicin, and with the exception of hygromycin, several other aminoglycoside antibiotics [6] . Given that many of the mycobacterial genetic tools use kanamycin or gentamicin resistance determinants, the cross-resistance of the AAC(3)-IV enzyme limits the utility of the aacC4 gene in the mycobacterial field.
To circumvent this problem, we undertook a chemical mutagenesis approach to isolate a mutant allele of the E. coli aacC4 gene that still confers resistance to apramycin but has a reduced ability to confer resistance to kanamycin and gentamicin. This mutant allele was used to produce modified E. coli-mycobacterial shuttle vectors applicable to a variety of uses.
Materials and methods

Strains, culture conditions, and plasmids
The bacterial strains and plasmids used in this work are shown in Table 1 and in Fig. 1 . E. coli was grown in Luria-Bertani (LB) broth or on LB agar. M. smegmatis was grown in LB broth supplemented with 0.5% (w/v) Tween-80 (LBT) or on LB agar, while M. bovis BCGPasteur and M. tuberculosis H37Rv were grown in Middlebrook 7H9 broth or 7H10 plates [7] . Plasmid transformations of E. coli and mycobacteria were done as previously described [7] . DNA was manipulated using standard methods [8] . DNA sequence data were obtained by ACTG, Inc. (Northbrook, IL). Reagents and antibiotics were obtained from Sigma-Aldrich Chemicals or ICN biochemicals. Minimal inhibitory concentration (MIC) values were obtained using the microdilution method [9] . Antibiotics were used at concentrations described in Sections 2.2 and 3.1 below.
Chemical mutagenesis of the aacC4 gene
The aacC4 gene was obtained from plasmid pJG1011 (a kind gift of William Bishai, Johns Hopkins University). A 1048 bp PstI-BsaAI DNA fragment bearing the Table 1 Strains and plasmids used in this study
Description
Source or Reference aacC4 gene was removed from pJG1011 and ligated to the PstI-SmaI sites of the E. coli plasmid pKSI þ (Stratagene) yielding pMP139. The plasmid pMP139 was subjected to hydroxylamine mutagenesis as previously described, except that the incubation time was 60 min [10] . The plasmid DNA was recovered from the mutagenesis reaction and used to transform competent E. coli DH10B to ampicillin resistance. The ampicillin resistant E. coli clones were picked and patched onto LB agar containing apramycin, kanamycin, or gentamicin, each at a concentration of 50 lg ml À1 .
Results and discussion
Isolation and characterization of the mutant aacC41 allele
We screened 427 ampicillin resistant E. coli clones bearing mutagenized pMP139 DNA and found one clone with an altered aminoglycoside resistance profile. The clone was resistant to apramycin but susceptible to kanamycin and gentamicin. The plasmid DNA (pMP348) was isolated from the clone and used to transform E. coli again and the altered resistance phenotype was confirmed. The mutated allele (aacC41) in plasmid pMP348 was sequenced and found to have two missense mutations, resulting in a threonine replacing alanine at position 51 and a tyrosine replacing a histidine at position 123. To determine if one or both of the mutations were required for the phenotype of this mutant, we constructed two derivative plasmids by swapping internal fragments of the mutant and wild type genes, resulting in mutant genes bearing only one of the mutations of the aacC41 allele (Table 2) . Plasmid pMP367 bears the aacC42 allele (A51T mutation), while the plasmid pMP390 bears the aacC43 allele (H123Y mutation). E. coli cells containing these plasmids were subcultured onto solid media containing each of the three aminoglycoside antibiotics at 50 lg ml À1 . Only the plasmid pMP390, bearing the H123Y mutation, conferred resistance to apramycin but not to gentamicin or kanamycin, unlike pMP367 (A51T) which conferred resistance to all three antibiotics similar to the wild-type aacC4 gene (data not shown).
We aligned the protein sequence of the H123Y mutant to 15 other AAC(3) aminoglycoside acetyltransferases Fig. 1 . Plasmids bearing the mutant aacC41 gene. The genes and regions of each plasmid are shown; the restriction endonuclease sites have been removed for clarity. Plasmid maps with additional detail can be obtained from the corresponding author. Plasmid pMP348 is an E. coli vector that is the source of the aacC41 cassette. The cassette is flanked by multiple restriction endonuclease sites, allowing it to be used to mark a gene of interest for allelic exchange. The other plasmids are E. coli-mycobacterial shuttle vectors bearing the ColE1 replicon for E. coli (oriE) and the pAL5000 replicon for mycobacteria (oriM), or the mycobacteriophage integration system (attP/int). Plasmid pMP349 is a multi-copy vector containing the mycobacterial groEL promoter (P groEL ), while plasmid pMP395 has the P groEL replaced by the acetamide-regulated promoter of M. smegmatis (acetamide regulatory region, ARR). Plasmid pMP399 is similar to pMP349 but the oriM has been replaced with the int/attP integration system of mycobacteriophage L5. This plasmid integrates at single-copy via the attB site in the mycobacterial chromosome. with varying substrate specificities, but found no clear correlation between the mutation and antibiotic specificity (data not shown). The AAC(3)-IV enzyme is unusual in that it is one of only two that confer apramycin resistance [11] . A more detailed biochemical analysis of the H123Y mutant described in this study could help explain the structural parameters for substrate specificity of the aminoglycoside acetyltransferases, of which little is known.
To further characterize these mutant alleles in E. coli, we performed MIC determinations. As shown in Table  2 , E. coli cells bearing the wild-type aacC4 plasmid pMP139 were highly resistant to all three aminoglycosides, with a MIC value greater than 512 lg ml À1 . The mutant plasmids pMP348 (A51T, H123Y) and pMP390 (H123Y) both conferred the same high resistance to apramycin as wild-type, but had an MIC value for kanamcyin that was essentially the same as the vector control, approximately 16 lg ml À1 (Table 2) . Interestingly, the MIC values for gentamicin were only slightly decreased for the two mutants, with the double mutant slightly more affected. The MIC value for the double mutation aacC41 allele (pMP348) was 128 lg ml À1 , while the MIC value for the single mutation aacC43 allele (pMP390) was 256 lg ml À1 . This might suggest that the A51T mutation has a slight affect on the resistance phenotype in the presence of the H123Y mutation. However, given that the MIC value of gentamicin for the vector control was 4 lg ml À1 , there was not an increase in gentamicin susceptibility in the mutants as that seen for kanamycin by this assay. This might be due to subtle differences in the substrate specificity of the AAC(3)-IV enzyme, which has higher activities with apramycin and gentamicin substrates and lower activity with kanamycin as a substrate [6] .
However, to examine these changes in susceptibility from a practical standpoint we took each of the E. coli strains bearing these mutant plasmids and determined plating efficiencies of the strains on different aminoglycoside containing media. We plated 100 ll of saturated cultures of E. coli strains bearing the wild-type, control, and mutant plasmids onto LB agar containing 50 lg ml À1 of apramycin or kanamyin or varying concentrations of gentamicin. The wild-type aacC4 control strain grew as a confluent lawn of cells on all media tested, while the vector control strain did not grow (data not shown). In contrast, while both the E. coli strains bearing the mutant plasmids grew as a lawn of cells on the 50 lg ml À1 apramycin plates, they did not grow on the 50 lg ml À1 kanamycin plates or on gentamicin plates at or above 100 lg ml À1 (data not shown). Thus, although there is only a negligible difference in the gentamicin susceptibility of the mutants in liquid medium compared to wild-type, there is a significant difference on solid medium, sufficient to prevent cross-resistance.
Modification of mycobacterial shuttle plasmids
The mutant aacC41 allele (A51T, H123Y) was used for the construction of a series of E. coli-mycobacterial shuttle vectors as described in Table 2 and shown in Fig. 1 . We chose the aacC41 double mutation allele because its phenotype was slightly more affected than that of the aacC43 (H123Y) single mutation allele. The first shuttle plasmid, pMP349, is a replicating expression vector derived from the plasmid pMV261 [12] . The second shuttle plasmid, pMP395, is a derivative of plasmid pMP349, with the M. bovis BCG groEL promoter of pMP349 replaced with the M. smegmatis acetamidase-regulated promoter [13] . The third derivative is pMP399, a non-replicative, but integration-proficient vector derived from pMV361 [12] . This vector has the attP/int system from mycobacteriophage L5 and integrates at the attB site of the mycobacterial chromosome [14] . Shuttle plasmids bearing the mutant aacC41 allele were tested in M. smegmatis, M. bovis BCG substrain Pasteur, and M. tuberculosis strain H37Rv. The mutant allele conferred resistance to 50 lg ml À1 apramycin but not to kanamycin in these strains. Furthermore, we have found that the aacC41 allele does not confer gentamicin resistance to M. smegmatis on solid media containing 50 lg ml À1 gentamicin. This in contrast to what we observed above with E. coli, which had a gentamicin breakpoint of 100 lg ml À1 on solid medium. The difference between the two species may be due to difference in protein expression. The aacC41 gene is originally from E. coli and might be expressed at a lower level in the G + C rich mycobacteria because of differences in codon preference.
In summary, we have isolated a mutant allele of the aacC4 gene of E. coli that has greater utility as a genetic marker. The allele confers resistance to apramycin but does not confer resistance to kanamycin. The allele still confers some resistance to gentamicin under certain conditions but this can be overcome by using higher concentrations of the antibiotic on solid media. We have developed a series of E. coli-mycobacteria shuttle plasmids bearing this mutant allele, applicable to a variety of uses. The aacC41 gene cassette itself may also prove useful in genetic systems for other bacterial species that are susceptible to apramycin.
